
2seventy bio, Inc.
NASDAQ:TSVT
4.99 (USD) • At close April 30, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|---|---|
Revenue
| 37.862 | 100.387 | 91.496 | 54.522 | 248.122 | 44.296 | 54.579 |
Cost of Revenue
| 22.563 | 16.918 | 26.219 | 12.588 | 5.396 | 2.978 | 0.885 |
Gross Profit
| 15.299 | 83.469 | 65.277 | 41.934 | 242.726 | 41.318 | 53.694 |
Gross Profit Ratio
| 0.404 | 0.831 | 0.713 | 0.769 | 0.978 | 0.933 | 0.984 |
Reseach & Development Expenses
| 76.917 | 230.758 | 248.735 | 261.937 | 296.467 | 297.645 | 200.49 |
General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 43.924 | 69.414 | 79.45 | 93.506 | 90.897 | 81.646 | 53.631 |
Other Expenses
| 9.888 | 20.905 | 6.055 | 21.647 | 18.056 | 20.126 | 19.163 |
Operating Expenses
| 130.729 | 321.077 | 328.185 | 355.443 | 387.364 | 379.291 | 254.121 |
Operating Income
| -115.43 | -237.608 | -262.908 | -313.509 | -144.638 | -337.973 | -203.426 |
Operating Income Ratio
| -3.049 | -2.367 | -2.873 | -5.75 | -0.583 | -7.63 | -3.727 |
Total Other Income Expenses Net
| 58.183 | 20.038 | 8.755 | 21.296 | 24.524 | 17.379 | 3.677 |
Income Before Tax
| -57.247 | -217.57 | -254.153 | -292.213 | -120.114 | -320.594 | -199.749 |
Income Before Tax Ratio
| -1.512 | -2.167 | -2.778 | -5.36 | -0.484 | -7.238 | -3.66 |
Income Tax Expense
| 0 | 0 | -0.009 | -15.999 | 18.056 | 2.747 | 19.163 |
Net Income
| -57.247 | -217.57 | -254.144 | -276.214 | -138.17 | -323.341 | -199.749 |
Net Income Ratio
| -1.512 | -2.167 | -2.778 | -5.066 | -0.557 | -7.3 | -3.66 |
EPS
| -1.1 | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
EPS Diluted
| -1.1 | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
EBITDA
| -115.43 | -206.418 | -251.375 | -297.159 | -131.45 | -329.186 | -187.082 |
EBITDA Ratio
| -3.049 | -2.056 | -2.747 | -5.45 | -0.53 | -7.432 | -3.428 |